bioRxiv · 10.1101/082552
Methods for detecting co-mutated pathways in cancer samples to inform treatment selection
Abstract
Tumor genomes evolve through a selection of mutations. These mutations may complement each other to promote tumorigenesis. To better understand the functional interactions of different processes in cancer, we studied mutation data of a set of tumors and identified significantly co-mutated pathways. Fishers exact test is a standard approach that can be used to assess the significance of the joint dysregulation of pathways pairs across a patient population. We developed a robust test to identify co-occurrence using DNA mutations, which overcomes deficiencies of the Fishers exact test by taking into account the large variability in overall mutation load and sequencing depth. Applying our method to a study of six common cancer types, we identify enrichment of co-mutated signal transduction pathways such as IP3 synthesis and PI3K and pairs of co-mutated pathways involving other processes such as immunity and development. We observed enrichment of clonal co-mutation of the proteasome and apoptosis pathways in colorectal cancer, which suggests potential mechanisms for immune evasion.
Explore related subjects
Keep this discovery
Jiang, T., Shaham, U., Parisi, F., Halaban, R., Safonov, A., Kluger, H., Weissman, S., Chang, J., Kluger, Y.. 2016-10-22. Methods for detecting co-mutated pathways in cancer samples to inform treatment selection. https://doi.org/10.1101/082552
Cite the original work for its findings. Save a collection to share your selection of sources.